AssetMark Inc
SGMO

AssetMark Inc’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

AssetMark Inc’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,694
Closed -$35K – 1420
2019
Q1 		$35K Sell
3,694
-504
-12% -$5.15K ﹤0.01% 768
2018
Q4 		$48K Buy
4,198
+61
+1% +$758 ﹤0.01% 697
2018
Q3 		$70K Buy
4,137
+140
+4% +$2.13K ﹤0.01% 674
2018
Q2 		$57K Buy
3,997
+2,113
+112% +$35.1K ﹤0.01% 696
2018
Q1 		$36K Buy
+1,884
New +$40.3K ﹤0.01% 815

Other funds holding SGMO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AssetMark Inc's SGMO Position: Q2 2019 in Review

AssetMark Inc sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2019, closing a stake of 3,694 shares — an estimated $35K sold.

AssetMark Inc first reported a position in SGMO in Q1 2018 and held it in 5 quarters. The position peaked at $70K in Q3 2018. 185 funds tracked by Wall St. Rank hold SGMO as of Q2 2019.

  • AssetMark Inc reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2019 after selling out during the quarter.
  • AssetMark Inc sold 3,694 SANGAMO THERAPEUTICS INC shares in Q2 2019, an estimated $35K.
  • AssetMark Inc first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 5 quarters.
  • AssetMark Inc's SANGAMO THERAPEUTICS INC position peaked at $70K in Q3 2018.
  • 185 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2019.

Based on AssetMark Inc's 13F filing for Q2 2019, filed 14 Aug 2019.